HCPLive

FDA Approves Ravicti for Urea Cycle Disorders

 
FDA Approves Ravicti for Urea Cycle DisordersFRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia build-up can lead to coma, brain damage, or death, the FDA said Friday in a news release.

Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.

Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence, and headache.

Ravicti is marketed by Hyperion Therapeutics, based in San Francisco.
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

The fittest seniors are half as likely as others to suffer from heart failure, according to research published in the July 1 issue of JACC: Heart Failure.

Increased numbers of small cancers and precancerous lesions are found in geographical areas where more mammograms take place; however, the higher screening rates are not associated with reduced breast cancer mortality, according to a study published online July 6 in JAMA Internal Medicine.

For many cancers, mortality rates are declining and are expected to meet Healthy People 2020 (HP2020) targets, according to a study published online July 2 in the US Centers for Disease Control and Prevention's Preventing Chronic Disease.

Telemedicine monitoring is not associated with any significant difference in amputation or healing, but may be linked to increased mortality for patients with diabetic foot ulcers, according to a study published online June 26 in Diabetes Care.

$vAR$